Calithera Biosciences (NASDAQ:CALA) Vs. LTRN, AKTX, EYEN, DMAC, BCEL, AKBA, MTEM, ONCY, BOLT, and SEEL
Should you be buying Calithera Biosciences stock or one of its competitors? The main competitors of Calithera Biosciences include Lantern Pharma (LTRN), Akari Therapeutics (AKTX), Eyenovia (EYEN), DiaMedica Therapeutics (DMAC), Atreca (BCEL), Akebia Therapeutics (AKBA), Molecular Templates (MTEM), Oncolytics Biotech (ONCY), Bolt Biotherapeutics (BOLT), and Seelos Therapeutics (SEEL). These companies are all part of the "pharmaceutical preparations" industry.
Calithera Biosciences vs.
Calithera Biosciences (NASDAQ:CALA) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, community ranking, institutional ownership, earnings, profitability and risk.
Lantern Pharma has lower revenue, but higher earnings than Calithera Biosciences. Lantern Pharma is trading at a lower price-to-earnings ratio than Calithera Biosciences, indicating that it is currently the more affordable of the two stocks.
55.8% of Calithera Biosciences shares are held by institutional investors. Comparatively, 34.2% of Lantern Pharma shares are held by institutional investors. 11.9% of Calithera Biosciences shares are held by insiders. Comparatively, 30.3% of Lantern Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Calithera Biosciences had 5 more articles in the media than Lantern Pharma. MarketBeat recorded 5 mentions for Calithera Biosciences and 0 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.84 beat Calithera Biosciences' score of -0.23 indicating that Lantern Pharma is being referred to more favorably in the news media.
Calithera Biosciences has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.
Lantern Pharma's return on equity of -19.12% beat Calithera Biosciences' return on equity.
Calithera Biosciences received 330 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 81.82% of users gave Lantern Pharma an outperform vote while only 69.04% of users gave Calithera Biosciences an outperform vote.
Calithera Biosciences presently has a consensus price target of $2.50, indicating a potential upside of 1,101.92%. Lantern Pharma has a consensus price target of $32.50, indicating a potential upside of 441.67%. Given Calithera Biosciences' higher probable upside, equities research analysts clearly believe Calithera Biosciences is more favorable than Lantern Pharma.
Summary
Lantern Pharma beats Calithera Biosciences on 8 of the 15 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Calithera Biosciences (NASDAQ:CALA) vs. Its Competitors
Calithera Biosciences Competitors List
